U.S., Nov. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07223021) titled 'A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia' on Oct. 28.
Brief Summary: The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletio (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who will receive tisagenlecleucel CAR T-cell therapy. We will compare PK-targeted fludarabine dosing with standard fludarabine dosing to see which treatment approach is more effective. The researchers will also look at whether PK-targeted fludarabine dosing is feasible (practical), the side ef...